Endogene Opioide (Endorphine, Enkephaline)

  • Enno Freye

Zusammenfassung

Die endogenen Opioide haben aller Wahrscheinlichkeit nach eine entwicklungsgeschichtlich entscheidende Bedeutung beim Überlebenskampf erlangt. Denn bei den unter einer Belastungssituation ausgelösten Reaktionen des protektiven Systems sind endogene Opioide in der Lage, diese zu blockieren, wenn sie zum Überleben (Flucht oder Kampf) des Individuums nur hinderlich sind:

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 1.
    Wahl C (1987) »Was Ihr wollt« - zur statistischen Einschätzung von Konsum, Mißbrauch und Abhängigkeit bei legalen und illegalen Drogen. In: Ness B, Wahkl C, Ziegler H (Hrsg) Jahrbuch zur Frage der Suchtgefahren. Neuland, Hamburg, pp 89Google Scholar
  2. 2.
    Henderson G (1988) Designer drugs: The new synthetic drugs of abuse. Clinical update in toxicology. Du Pont Pharmaceuticals, Delaware/WIGoogle Scholar
  3. 3.
    Sahihi A (1989) Designer-Drogen. Die neue Gefahr. Beltz, Weinheim BaselGoogle Scholar
  4. 4.
    Scheerer S (1989) Die Heroinszene. In: Scheerer S, Vogt I (Hrsg) Drogen und Drogenpolitik. Campus, Frankfurt am Main, pp 285–299Google Scholar
  5. 5.
    Christiani E, Stübing G (1972) Drogenmissbrauch und Drogenabhängigkeit. Deutscher Ärzteverlag, KölnGoogle Scholar
  6. 6.
    Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 197–258CrossRefGoogle Scholar
  7. 7.
    Jasinski DR, Pevnik JS, Griffith JD (1978) Human pharmacology and the abuse potential of the analgesic bupre-norphine. Arch Gen Psychiatry 35: 501–516PubMedCrossRefGoogle Scholar
  8. 8.
    Lewis JW, Walter D (1992) Buprenorphine-background to its development as a treatment for opioid dependence. NIDA Res Monogr 121: 5–11PubMedGoogle Scholar
  9. 9.
    Abbott A (1992) Neurobiological perspectives on drugs of abuse. Trends Pharmacol Sei 13: 169CrossRefGoogle Scholar
  10. 10.
    Ramsey NF, van Ree JM (1992) Reward and abuse of opiates. Pharmacol Toxicol 71 /2: 81–94PubMedCrossRefGoogle Scholar
  11. 11.
    DiChiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244 /3: 1067–1080Google Scholar
  12. 12.
    Thomas DN, Fontana DJ, Post RM, Weiß SRB, Pert A (1993) The involvement of the mesocorticolimbic dopamine system in the conditioned effects of cocaine. In: Harris L (ed) Problems of drug dependence. Proceedings of the 54th Annual Scientific Meeting 1992. NIDA, Rockville. Vol 260, PP 132Google Scholar
  13. 13.
    Wang Y, Bilsky E, Porreca F, Sadee W (1994) Constitutive p opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54: 339–350Google Scholar
  14. 14.
    Sadee W, Wang Z (1993) Constitutive fj opioid receptor activation can account for narcotic tolerance and dependence. Proceedings International Narcotics Research Conference (INRC). Uppsala Universitet Reprocentralen HSC, Skövde/Sweden, p 102Google Scholar
  15. 15.
    Piepenbrock S, Hempelmann G, Peters H (1977) Veränderungen der Hämodynamik der Herzinotropie und des myocardialen Sauerstoffverbrauchs nach Antagonisierung von hohen Dosen von Fentanyl mit Naloxon. Prakt Anästh 12: 275Google Scholar
  16. 16.
    Freye E, Härtung E (1982) Naloxone induces excitation of the cardiovascular system and a rise in myocardial oxygen consumption in fentanyl and meperidine-anesthetized dogs. Acta Anaesth Belg 33: 89–97PubMedGoogle Scholar
  17. 17.
    Höllt V, Przewlocki R, Herz A (1978) ß-Endorphin-like immunoreactivity in plasma, pituitaries and hypothalamus of rats following treatment with opiates. Life Sci 23: 1057PubMedCrossRefGoogle Scholar
  18. 18.
    Goldstein DB, Goldstein A (1961) Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmacol 8: 48–53CrossRefGoogle Scholar
  19. 19.
    Zola EM, MacLeod DC (1983) Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm 17: 411–417PubMedGoogle Scholar
  20. 20.
    Cookson RF (1983) Carfentanil and lofentanil. Clin Anaesthesiol 1: 156–158Google Scholar
  21. 21.
    Langston JW, Ballard P, Tetrud JW, I (1983) I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980Google Scholar
  22. 22.
    Langston JW, Irwin J, E. B. L, Forno LSC (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482PubMedCrossRefGoogle Scholar
  23. 23.
    Freye E (1999) Opioide in der Medizin, 4. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  24. 24.
    Freye E (1992) Medikamenteninteraktion bei der Metha-dontherapie. Z Ärztl Fortbild 86: 731–737Google Scholar
  25. 25.
    Schuster S, Weilemann LS, Meyer J (1989) Drogennotfälle. Notarzt 5: 23–28Google Scholar
  26. 26.
    Kreek MJ (1973) Medical safety and side effects of methadone in tolerant individuals. JAMA 233: 665–668CrossRefGoogle Scholar
  27. 27.
    Kreek MJ, Khuri E, Flomenberg N, Albeck H, Ochshorn M (1989) Immune status of unselected methadone maintained former heroin addicts. In: Quiron R, Jhamandas K, Gianoulakis C (eds) The International Narcotics Research Conference (INRC) ‘89. Liss, New York. Progress in clinical and biological research, vol 328, pp 445–448Google Scholar
  28. 28.
    Latasch L, Schneider M, Steinau U (1986) Morphologische Befunde an Skelettmuskelbiopsien bei Heroinabhängigen. Klinikarzt 15: 252Google Scholar
  29. 29.
    McCammon RL (1986) Anesthesia for the chemically dependent patient. In: Review Course Lectures 1986. International Anesthesia Research Society (IARS), Cleveland, pp 47–55Google Scholar
  30. 30.
    Martin WR, Jasinski DR, Haertzen CA et al. (1973) Methadone–A réévaluation. Arch Gen Psychiatry 28: 286–295PubMedCrossRefGoogle Scholar
  31. 31.
    Freye E, Schenk GK (1990) Methadon als Ersatztherapie beim Opiatabhängigen? Klinikarzt 2: 57–61Google Scholar
  32. 32.
    Mark LC (1966) Hypotension during anesthesia in narcotic addicts. N Y State J Med 66: 2685–2695Google Scholar
  33. 33.
    Martin WR, Jasinski DR (1977) Assessment of the abuse potential of narcotic analgesics in animal. In: Martin WR (ed) Drug addiction. I. Morphine, sedative/hypnotic and alcohol dependence. Handbook of experimental pharmacology, vol 45/I. Springer, Berlin Heidelberg New YorkGoogle Scholar
  34. 34.
    Dole VP, Nyswander ME (1965) A medical treatment for diacethylmorphine (heroin-) addiction. JAMA 193: 646–650PubMedCrossRefGoogle Scholar
  35. 35.
    Winkler KR (1980) Zur Strafbarkeit des Arztes gemäß § 11 Abs. 1 Nr. 9 Betäubungsmittelgesetz. Suchtgefahren 26: 28–37Google Scholar
  36. 36.
    Rösinger C, Gastpar M (1991) Methadonsubstitution in der Behandlung schwerkranker Opiatabhängiger. Dtsch Ärztebl 44: C-2079-C-2088Google Scholar
  37. 37.
    Franke M (1985) Übergeordnete Gesichtspunkte zur Bewertung von Methadonprogrammen. Suchtgefahren 31: 95–100Google Scholar
  38. 38.
    Hartmann H, Uchtenhagen A, Fuchs W, Pasi A (1984) Hausärztliche Methadonbehandlung bei Heroinabhängigen. Schweiz Rundschau Med 73: 299–304Google Scholar
  39. 39.
    Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N (1976) Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 21: 147–157Google Scholar
  40. 40.
    Keup W (1978) Methadon-Erhaltungsprogramme. Dtsch Ärztebl 18: 1179–1182Google Scholar
  41. 41.
    Beaver WT, Wallentein SL, Houde RW, Roger A (1976) A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally administered methadone. Clin Pharmacol Ther 8: 415–426Google Scholar
  42. 42.
    Olsen GD, Livermore JD, Wendel HA et al. (1976) Methadone induced respiratory depression in female methadone maintenance subjects. Clin Res 24: 388 AGoogle Scholar
  43. 43.
    Brune K, Dietzel K, Möller N (1986) Pharmakologie des Schmerzes-Abhängigkeit, Sucht. In: Wörz R (Hrsg) Pharmakologie bei Schmerz. Edition Medizin VCH, Weinheim, pp 120–134Google Scholar
  44. 44.
    Nielsson MI (1982) Clinical pharmacokinetics of methadone. University Press, Upp sala/Sweden (Thesis )Google Scholar
  45. 45.
    lnturrisi CE (1973) Disposition of methadone in man after single oral dose. Clin Pharmacol Ther 13: 923–930Google Scholar
  46. 46.
    Nielsson MJ, Widerloev E, Meresaar U, nggard E (1982) Effect of urinary ph on the disposition of methadone in man. Eur J Clin Pharmacol 22: 331–342Google Scholar
  47. 47.
    Romach MK, Piafsky KM, Abel JG, Khouw V, Seilers EM (1981) Methadone binding to orosomucoid (alphal-acid-glucoprotein). Determinant of free fraction in plasma. Clin Pharmacol Ther 21: 307–321Google Scholar
  48. 48.
    Goldfrank L, Flamenbaum N, Weismann RS (1981) General management of the poisened overdosed patient. Part 1. Patients in coma with altered mental status. Hosp Physician 17: 24–62Google Scholar
  49. 49.
    Kreek MJ, Gutjahr CL, Garfield JN, Bowen DV, Field FH (1976) Drug interactions with methadone. Ann N Y Acad Sei 281: 350–370CrossRefGoogle Scholar
  50. 50.
    Novick DM, Kreek MJ, Fanizza AH, Yancovitz SR, Gelb AM, Stenger RM (1981) Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 30: 353–362PubMedCrossRefGoogle Scholar
  51. 51.
    Blinick G, Wallach RC, Jerez E (1969) Pregnancy in narcotic addicts treated by medical withdrawal. The methadone detoxification program. Am J Obst Gynecol 105: 997–1003Google Scholar
  52. 52.
    Rothstein P, Gould JB (1974) Born with a habit–Infants of drug addicted mothers. Pediatr Clin North Am 21: 307–321PubMedGoogle Scholar
  53. 53.
    Geber WF, Schramm LC (1975) Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 12: 705–713Google Scholar
  54. 54.
    Gourlay GK, Wilson PR, Glynn GJ (1982) Pharmacodynamics and pharmacokinetics of methadone during the operative period. Anesthesiology 57: 458–467PubMedCrossRefGoogle Scholar
  55. 55.
    Freye E (1987) Opioid agonists, antagonists and mixed narcotic analgesics. Theoretical background and considerations for practical use. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  56. 56.
    De Castro J, Viars P (1968) Utilisation pratique des analgésiques centraux en anesthésie et réanimation. Ars Med 23: 74–74Google Scholar
  57. 57.
    Liebson I, Bigelow G, Flamer R (1971) Alcoholism among methadone patients; a specific treatment method. Am J Psychiat 130: 483–485Google Scholar
  58. 58.
    Stimmel B, Hanburg R, Stuniano V, Korts D, Jackson G, Cohen M (1982) Alcoholism as a risk factor in methadone maintenance. Am J Med 73: 631–636PubMedCrossRefGoogle Scholar
  59. 59.
    Chabalko J, La Rosa J, du Pont RL (1973) Death of methadone users in the district of Columbia. Int J Addict 8: 897–908PubMedGoogle Scholar
  60. 60.
    Schulte RM (1986) Medikamentenabhängigkeit und Poly-toxikomanie. Ergebnisse einer empirischen Untersuchung bei Drogenabhängigen und Alkoholikern. Dtsch Ärztebl 83: 3451Google Scholar
  61. 61.
    Olson GD, Bennett WM, Porter GA (1975) Morphine and Phenytoin binding to human plasma protein in renal and hepatic failure. Clin Pharmacol Ther 17: 677Google Scholar
  62. 62.
    Sifton DW (1988) Drug Interaction and Side Effects Index, Physicians Desk Reference (PDR) 42th Edn. Medical Economics Company, Oradell, N.Y.Google Scholar
  63. 63.
    De Castro J (1971) Association des analgésiques centraux et des neuroleptiques en cours d’intervention. In: Vourch G, De Castro J, Gauthier-Lafaye P, Guidicelli JF, Viars P (eds) Les analgésiques et la douleur. Influences pharma-cologiques diverses exercées sur morphiniques. Masson, Paris, pp 185–194Google Scholar
  64. 64.
    Freye E (1991) Opioide in der Medizin. Wirkung und Einsatzgebiete zentraler Anal getika, 2. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  65. 65.
    Bewley TH, Ghodse AH (1984) Opiate analgesics and narcotic antagonists. In: Dukes MNG (ed) Meyler’s side effects of drugs, 10th Edn. Elsevier, Amsterdam, pp 120–134Google Scholar
  66. 66.
    Elstrom J (1977) Plasma protein binding of phenytoin after cholecystectomy and neurosurgical operations. Acta Neur Scand 55: 455CrossRefGoogle Scholar
  67. 67.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New YorkGoogle Scholar
  68. 68.
    Keup W (1983) Clonidin–seine Möglichkeiten in der Pharmakotherapie der Heroin abhängigkeit. Dtsch Ärztebl 80 /3: 25–32Google Scholar
  69. 69.
    Gold MS, Pottash AC, Sweeney DR, Kleber HD (1980) Opiate withdrawal using Clonidin. A safe, effective, and rapid nonopiate treatment. JAMA 243: 343–348Google Scholar
  70. 70.
    Groß A, Soyka M (1999) Buprenorphin–ein neuer Ansatz in der Pharmakotherapie opiatabhängiger Patienten. Suchtmed 1: 5–14Google Scholar
  71. 71.
    Kosten TR, Morgan C, Kleber HD (1992) Phase II clinical trials of buprenorphine: Detoxification and induction into naltrexone. NIDA Res Monogr 121: 101–119Google Scholar
  72. 72.
    Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J (1993) Buprenorphine versus methadone maintenance for opioid dependence. J Nev Ment Dis 181 /6: 358–364CrossRefGoogle Scholar
  73. 73.
    Guthrie SK (1990) Pharmacologic interventions for the treatment of opioid dependence and withdrawal. Ann Pharmacother 24/7–8: 721–734Google Scholar
  74. 74.
    Bickel WK, Stitzler ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247 /1: 47–53PubMedGoogle Scholar
  75. 75.
    Woods JH, France CP, Winger GD (1992) Behavioral pharmacology of buprenorphine issues relevant to its potential in treating drug abuse. NIDA Res Monogr 121: 12–27PubMedGoogle Scholar
  76. 76.
    Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence. A review. Exp Clin Psychopharmacol 3: 477–489Google Scholar
  77. 77.
    Fudala PJ, Johnson RE, Bunker E (1989) Abrupt withdrawal of buprenorphine following chronic administration. Clin Pharmacol Ther 186/2: IVB-1Google Scholar
  78. 78.
    Mello NK, Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207: 657–659PubMedCrossRefGoogle Scholar
  79. 79.
    Mendelson JH, Mello NK, Teoh SK, Kuehnle J, Sintavana-rong P (1991) Buprenorphine treatment for concurrent heroin and cocaine dependence: phase I study. NIDA Research Monograph Series 105, pp 196–202Google Scholar
  80. 80.
    Mendelson JH, Mello NK (1992) Human laboratory studies of buprenorphine. NIDA Res Monogr 121: 38–60PubMedGoogle Scholar
  81. 81.
    Auriacombe M, Franques P, Bertorelle V, Tignol J (1999) Use of buprenorphine for substitution treatment–a French experience in Bordeaux and Bayonne. Res Clin For 19: 47–50Google Scholar
  82. 82.
    Kosten TR, Morgan C, Kleber HD (1991) Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 17 /2: 119–128PubMedCrossRefGoogle Scholar
  83. 83.
    Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N (1992) Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 28 /1: 109–113PubMedGoogle Scholar
  84. 84.
    Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261 /3: 985–993PubMedGoogle Scholar
  85. 85.
    Blaine JD (1992) Buprenorphine: an alternative treatment for opioid dependence. NIDA Res Monogr 121: 1–4Google Scholar
  86. 86.
    Marion IJ (1955) LAAM in the treatment of opiate addiction. Treatment improvement protocol (TIP), vol 22, US Department of Health and Human Services Washington DCGoogle Scholar
  87. 87.
    Ling W, Rawson RA, Compton MA (1994) Substitution pharmacotherapies of opioid addiction from methadone to LAAM and buprenorphine. J Psycho Drugs 26: 119–128CrossRefGoogle Scholar
  88. 88.
    Verebey K, Volavka J, Mule SJ, Resnik RB (1976) Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 20: 315–328Google Scholar
  89. 89.
    Eberlein HJ (1982) Narkose nach Heroinentzug. Dtsch Med Wochenschr 107: 1819Google Scholar
  90. 90.
    Freye E (1992) Die perioperative Behandlung des Arzneimittelabhängigen. Anästh Intensiv med 3: 59–67Google Scholar
  91. 91.
    Giuffrida JG, Bizzari DV, Saure AC, Sharoff RL (1970) Anesthetic management of drug abusers. Anesth Analg 49: 272–278PubMedCrossRefGoogle Scholar
  92. 92.
    Eismann B, Lam RC, Rush B (1964) Surgery in the narcotic addict. Ann Surg 159: 748–759CrossRefGoogle Scholar
  93. 93.
    Rapp SE, Ready LB, Nessly ML (1995) Acute pain management in patients with prior opioid consumption: a case.- controlled retrospective review. Pain 61: 195–201PubMedCrossRefGoogle Scholar
  94. 94.
    Hughes JR, Bickel WK, Hggins ST (1991) Buprenorphine for pain relief in a patient with drug abuse. Am J Drug Alcohol Abuse 17 /4: 451–455PubMedCrossRefGoogle Scholar
  95. 95.
    Gelfand ML, Hammer H, Hevizy J (1967) Asymptomatic pulmonary atelactasis in drug addicts. Dis Chest 53: 782–786CrossRefGoogle Scholar
  96. 96.
    Bschor F (1987) Zur Revision des Abstinenzparadisgmas in der Behandlung Sucht kranker. Ambulante, medikamen-tengestützte Therapie, ein möglicher ärztlicher Beitrag zur AIDS-Prävention. Dtsch Med Wochenschr 112: 907PubMedCrossRefGoogle Scholar
  97. 97.
    Singarajah C, Lavies NG (1992) An overdose of ecstasy. Anaesthesia 47: 686–687PubMedCrossRefGoogle Scholar
  98. 98.
    Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (»ectasy«). Lancet 340: 384–387PubMedCrossRefGoogle Scholar
  99. 99.
    Dowling GP, McDonough ET, Bost RO (1987) »Eve« and »ecstasy«: A report of five deaths with the use of MDEA and MDMA. JAMA 257: 1615–1617Google Scholar
  100. 100.
    Gouzoulis E, Borchardt D, Hermle L (1993) A case of toxic psychosis induced by »Eve« (3,4-methylenedioxyethyl-amphetamine). Arch Gen Psychiatry 50: 75PubMedCrossRefGoogle Scholar
  101. 101.
    Manchada S, Conolly MJ (1993) Cerebral infraction in association with ecstasy. Postgrad Med J 69: 874–875CrossRefGoogle Scholar
  102. 102.
    Freye E (1997) Kokain, Ecstasy und verwandte Designerdrogen - Wirkungsweise, Überdosierung, therapeutische Notfallmaßnahmen. Barth, Heidelberg LeipzigGoogle Scholar
  103. 103.
    Täschner KL (1994) Drogen und Straßenverkehr. Dtsch Ärzte Z 35Google Scholar
  104. 104.
    Külpmann WR. Feststellung des Beigebrauchs bei der Methadon-Substitutions behandlung von i.v.-Heroinabhängigen. Dtsch Ärztebl 1994 2: C-149-C-151Google Scholar
  105. 105.
    Baselt RC (1982) Disposition of toxic drugs and chemicals in man, 2nd Edn. Davis Biomedical Publ, PhiladelphiaGoogle Scholar
  106. 106.
    Hawks RL, Chiang CN (1986) Urine testing for drugs of abuse. US Department of Health and Human Servivces (NIH), Rockville/MD Maryland, NIDA Research Monograph Series, vol 73Google Scholar
  107. 107.
    Blum K (1984) Handbook of abusable drugs. Gardner, New YorkGoogle Scholar
  108. 108.
    Ladewig D, Stohler L (1994) Das Opiatentzugssyndrom–Skalierung und medikamentöse Strategien. In: Tretter F, Busello-Spieth W, Bender WH (Hrsg) Therapie von Ent-zugssyndromen. Springer, Berlin Heidelberg New York Tokio, pp 144–168Google Scholar
  109. 109.
    Loimer N, Schmid RW, Presslich O, Lenz K (1989) Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 23: 81–86PubMedCrossRefGoogle Scholar
  110. 110.
    Loimer N, Lenz K, Schmid R, Presslich O (1991) Technique for greatly shortening the transition from methadone to naltrexone maintenence of patients addicted to opiates. Am J Psychiat 148: 933–935PubMedGoogle Scholar
  111. 111.
    Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21: 253–259PubMedCrossRefGoogle Scholar
  112. 112.
    Legarda L, Gossop H (1994) A 24 hour inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Depend 35: 91–93PubMedCrossRefGoogle Scholar
  113. 113.
    Tretter F (1996) Von der Phantasie, die Sucht auszuschlafen. MMW 138: 76–77Google Scholar
  114. 114.
    Tretter F, Burkhardt D, Buzello-Spieth S, Reiss J, Walcher S, Büchele W (1996) Anwendungsverfahren mit dem forcierten Opiatentzug in Narkose. MMW 138: 787–791Google Scholar
  115. 115.
    Reiss J (1996) Drogenentzug unter Narkose–Eine Konsequenz der Substitutionstherapie. Fortschr Med 24: 12–13Google Scholar
  116. 116.
    Klienbaum P, Thürauf N, Michel MC, Scherbaum N, Gaspar M, Peters J (1998) Profound increase in epinephrine in plasma and cardiovascular stimulation after p-opiate receptor blockade in opiate addicted patients during barbiturate-induced anesthesia for acute detoxyfication. Anesthesiology 88: 1154–1161CrossRefGoogle Scholar
  117. 117.
    Glen JB (1998) The development of »Diprifusor«: a TCI system for propofol. Anaesthesia S3: 13–21CrossRefGoogle Scholar
  118. 118.
    Charney DS, Heninger GR, Kleber HD (1986) The combined use of Clonidine and naltrexone a rapid, safe, and effective treatement of abrupt withdrawal from methadone. Am J Psychiatry 143 /7: 831–837PubMedGoogle Scholar
  119. 119.
    Vining DH, Kosten TR, Kleber HD (1988) Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 63: 567–575CrossRefGoogle Scholar
  120. 120.
    Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13/1, 2: 1–17CrossRefGoogle Scholar
  121. 121.
    Ghignone M (1987) Effects of Clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 67: 3–10PubMedCrossRefGoogle Scholar
  122. 122.
    Engelman E, Lipzyc M, Gilbert E et al. (1989) Effects of Clonidine on anesthetic requirements and hemodynamic response during aortic surgery. Anesthesiology 71: 178–187PubMedCrossRefGoogle Scholar
  123. 123.
    Wilcox GL, Carlson GH, Joachim A, Jurna I (1987) Mutual potentiation of antinociceptive effects of morphine and Clonidine on motor and sensory responses in rat spinal cord. Brain Res 405: 84–93PubMedCrossRefGoogle Scholar
  124. 124.
    Redmond DE, Hwang YH (1982) The primate locus coeru-leus and affects of Clonidine on opiate withdrawal. J Clin Psychiatry 43: 25–31PubMedGoogle Scholar
  125. 125.
    Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus ceruleus: New evidence for anatomical and physiological specificity. Physiol Rev 63: 844–895Google Scholar
  126. 126.
    Jarrot B, Conway EL, Maccarone C, Lewis SJ (1987) Clonidine: understanding its disposition, sites and mechanism of action. Clin Exp Pharmacol Physiol 14: 471–479CrossRefGoogle Scholar
  127. 127.
    Freye E (1999) Elektroenzphalograpie, spinal und morto-risch evozierte Potentiale. In: Jantzen JP, Löffler W (Hrsg) Neuroanästhesie. Thieme, Stuttgart, pp 155–191Google Scholar
  128. 128.
    Sigl JC, Chamoun NG (1994) An introduction to bispectral analysis for the EEG. J Clin Monit 10: 392–404PubMedCrossRefGoogle Scholar
  129. 129.
    Freye E, Grabitz K, Sandmann W (1996) Was bringt die 3. Generation im Neuro monitoring für die klinische Praxis? Anästhesiol Intensivmed 3: 120–127Google Scholar
  130. 130.
    Blumberg H, Dayton HB (1974) Naloxone, naltrexone, and related noroxymorphones. In: Braude MC, Harris LS, Smith MJP, Villareal JE (eds) Narcotic antagonists. Raven, New York (Adv Biochem Psychopharm) vol 8, pp 33–43Google Scholar
  131. 131.
    Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28: 784–791PubMedCrossRefGoogle Scholar
  132. 132.
    Smith TC (1979) Comparison of naloxone and naltrexone in man. Anesthesiology 51: S 573CrossRefGoogle Scholar
  133. 133.
    Jenkins SA (1996) Somatostatin and octreotide. Medi-media Asia, Hong KongGoogle Scholar
  134. 134.
    North RA, Williams JT (1975) Enkephalines inhibit fireing of myenteric neurons. Nature 246: 460Google Scholar
  135. 135.
    Takeda T, Taniyama K, Baba S, Tanaka C (1989) Putative mechanisms involved in excitatory and inhibitory effects of somatostatin on intestinal motility. Am J Physiol 257: G 532-G 538Google Scholar
  136. 136.
    Williams J, North RA (1978) Inhibition offirering of myenteric neurones by somatostatin. Brain Res 155: 165–168PubMedCrossRefGoogle Scholar
  137. 137.
    Gagniella TS, O’Dorisio TM, Fassler JE, Mekhjian HS (1990) Treatment of endocrine and nonendocrine secretiory diarrheal states with Sandostatin®. Metabolism 39: 172–175CrossRefGoogle Scholar
  138. 138.
    Sehppard M, Shapairo B, Berelowitz M, Pimstone B (1979) Metabolic clearance and plasma half dissapearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48: 50–53CrossRefGoogle Scholar
  139. 139.
    Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187: 513–518PubMedCrossRefGoogle Scholar
  140. 140.
    Irifune M, Shimizu M, Nomoto M, Fukuda T (1992) Keta-mine induced anesthesia involves the N-methyl-D-aspar-tate receptor-channel complex in mice. Brain Res 569: 1–9CrossRefGoogle Scholar
  141. 141.
    Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–462PubMedCrossRefGoogle Scholar
  142. 142.
    Katz J, Kavanagh BP, Sandler AN (1992) Preemptive analgesia: clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439–446PubMedCrossRefGoogle Scholar
  143. 143.
    Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33: 11–23PubMedCrossRefGoogle Scholar
  144. 144.
    Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv 1995 21: 5–16Google Scholar
  145. 145.
    Brown JP, Boden P, Singh L, Gee NS (1996) Mechanimss of action of gabapentin. Rev Contemp Pharmacother 7: 203–214Google Scholar
  146. 146.
    Field MJ, Oles RJ, Lewis AS, McVlerary S, Hughes J, Singh L (1997) Gabapentin (neurontin) and S(f)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121: 1513–1522PubMedCrossRefGoogle Scholar
  147. 147.
    Mellik GA, Larry DO, Mellik B (1997) Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Reha-bil 78: 98–105CrossRefGoogle Scholar
  148. 148.
    Rosner H, Rubin L, Kestenbaum A (1996) Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 12: 56–58PubMedCrossRefGoogle Scholar
  149. 149.
    Sandyk R (1992) L-tryptophan in neuropsychiatric disorders: a review. Intern J Neurosci 67: 127–144CrossRefGoogle Scholar
  150. 150.
    Raffa RB, Friedrichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an »atypical« opioid analgesic. J Pharmacol Exp Ther 260 /1: 275–285PubMedGoogle Scholar
  151. 151.
    Sandyk R, Fisher H (1988) Serotonin in involuntary movement disorders. Intern J Neurosci 42: 185–205CrossRefGoogle Scholar
  152. 152.
    Sandyk R (1986) L-tryptophan in the treatment of restless legs syndrome. Am J Psychiatry 143: 554–555PubMedGoogle Scholar
  153. 153.
    Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G (1998) Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long term results. Drug Alcohol Depend 52: 243–250PubMedCrossRefGoogle Scholar
  154. 154.
    Yamaguchi K, Anderson JM (1992) Biocompatibility studies of naltrexone sustained release fomulations. J Cont Rel 19: 299–314CrossRefGoogle Scholar
  155. 155.
    Tefft JA, Roskos KV, Heller J (1992) The effect of lipase on release of naltrexone from triglycxeride-coated celllulose acetate phtalate micropheres. J Biomed Material Res 26: 713–724CrossRefGoogle Scholar
  156. 156.
    Holaday JW, Tortella FC (1984) Multiple opioid receptors: Possible physiological functions of m and 5 binding sites in vivo. In: Genazzini AR, Muller EE (eds) Central and peripheral endorphins: Basis and clinical aspects. Raven, New York, pp 237–250Google Scholar
  157. 157.
    Martin WR (1981) Mini-Symposium II. Multiple opioid receptors. Life Sci 28: 1547–1554PubMedCrossRefGoogle Scholar
  158. 158.
    Schmidhammer H, Smith CFC, Erlach D et al. (1990) Synthesis and biological evaluation of 14-Alkoxymorphinans. 3. Extensive study on cyprodime-related compounds. J Med Chem 33: 1200–1206PubMedCrossRefGoogle Scholar
  159. 159.
    Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: function and activity. Neurotransmissions 7 /1: 1–5Google Scholar
  160. 160.
    Takemori AE, Sofuoglu M, Sultana M, Nagase H, Porto-ghese PS (1990) Pharmacology of highly selective, non-peptide delta opioid receptor antagonists. In: van Ree JM, Mulder AH, Wiegant VM, van Wimersma Greidanus TB (eds) New leads in opioid research. Excerpta Medica, Amsterdam New York (International congress series), vol 914, pp 277–278Google Scholar
  161. 161.
    Romer D, Buscher H, Hill RC et al. (1980) Bremazocine: A potent, long-acting opiate kappa-agonist. Life Sci 27: 971–978PubMedCrossRefGoogle Scholar
  162. 162.
    Buzas B, Toth G, Cavagnero S, Hruby VJ, Borsodi A (1992) Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide [3H]deltorphin II. Life Sci 50: PL 75-PL 77Google Scholar
  163. 163.
    Rossier JT, Vargo M, Minick S, Ling N, Bloom EF, Guillemin R (1977) Regional dissociation of (3-endorphin and enkephalin contents in rat brain and pituitary. Proc Natl Acad Sci USA 74: 5262–5165CrossRefGoogle Scholar
  164. 164.
    Frederickson RCA, Geary LE (1982) Endogenous opioid peptides: Review of physiological, pharmacologiocal and clinical aspects. Prog Neurobiol 19: 16–69Google Scholar
  165. 165.
    Smith TW, Hughes J, Kosterlitz HW, Sosa RP (1976) Enkephalins: Isolation, distribution and function. Opiates and endogenous opioid peptides. Elsevier, AmsterdamGoogle Scholar
  166. 166.
    Feurle GE, Helmstaetter V, Weber U (1982) Met-and Leu-enkephalin immuno-and bio-reactivity in human stomach and pancreas. Life Sci 31: 2961–2969PubMedCrossRefGoogle Scholar
  167. 167.
    Kabayashi ST, Ushida T, Ohashi T et al. (1991) Met-eneke-phalin-Arg-Gly-Leu-like immunoractivity in adrenal chromaffin cells and carotid body chief cells of the dog and monkey. Biomed Res 4: 201–210Google Scholar
  168. 168.
    De Wald D, Lewis RV (1983) Enkephalin-containing polypeptide levels in normal tensive and SH rat adrenal glands. Peptides 4: 121–123CrossRefGoogle Scholar
  169. 169.
    Maysinger D, Hollt v, Seizinger BR, Mehraein P, Pasi A, Herz A (1982) Parallel distribution of immunoreactive alpha-neoendorphin and dynorphin in rat and human tissue. Neuropeptides 2: 211–225CrossRefGoogle Scholar
  170. 170.
    Czlonkowski A, Costa T, Przewlocki A, Pasi A, Herz A (1983) Opioid receptor binding in human spinal cord. Brain Res 267: 392–396PubMedCrossRefGoogle Scholar
  171. 171.
    Watson SJ, Akil H, Ghazarsson VE, Goldstein A (1981) Dynorphin immunocytochemical localization in brain and peripheral nervous system: prelimary studies. Proc Natl Acad Sci USA 78: 1260–1263PubMedCrossRefGoogle Scholar
  172. 172.
    Watson SJ, Khachaturian H, Akil H, Coy DH, Goldstein A (1982) Comparison of the distribution of dynorphin system and enkephalin system in brain. Science 218: 1134–1136PubMedCrossRefGoogle Scholar
  173. 173.
    Feuerstein G, Molineaux CJ, Rosensberg JG, Faden AD, Cox BM (1983) Dynorphin and Leu-Enkephalin in brain nuclei and pituitary of WKY and SHR rats. Peptides 4: 225–229PubMedCrossRefGoogle Scholar
  174. 174.
    Höckfelt T, Ljungdahl A, Terenius I, Eide R, Nilsson G (1977) Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P. Proc Natl Acad Sci USA 74: 3081CrossRefGoogle Scholar
  175. 175.
    Bruni JF, van Vugt D, Marschall S, Meilers J (1977) Effect of naloxone, morphine, methionine-enkephalin on serum prolactin, lutenizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci 21: 461PubMedCrossRefGoogle Scholar
  176. 176.
    Dupont A, Cusan L, Garon L, Labrie F, Li H (1977) ß-Endor-phin. Stimulation of growth hormone release in vivo. Proc Natl Acad Sci USA 74: 358Google Scholar
  177. 177.
    Shaar CJ, Frederickson RCA, Dinninger NB, Jackson L (1977) Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin. Evidence for regulation by an endgenous opioid peptide in brain. Life Sci 21: 853Google Scholar
  178. 178.
    Copolov DL, Helme RD (1983) Enkephalins and Endorphins Clinical, pharmacological and therapeutic implications. Drugs 26: 503–519PubMedCrossRefGoogle Scholar
  179. 179.
    Akil H, Richardson DE, Barchas JD, Li CH (1978) Appearance of ß-enorphin-like immunoreactivity in human ventricular cerebropinal fluid upon electrical stimulation. Proc Natl Acad Sci USA 75: 5170–5172PubMedCrossRefGoogle Scholar
  180. 180.
    Hosobuchi Y, Adams JE, Lichnitz R (1977) Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 197: 183PubMedCrossRefGoogle Scholar
  181. yama T, Jin T, Yamaha R (1980) Profound analgesic effects of ß-endorphin in man. Lancet I: 122–124Google Scholar
  182. 182.
    Genazzini AR, Nappi G, Facchinetti F et al. (1984) Progressive impairment of CSF ß- EP levels in migraine sufferers. Pain 18: 127–133CrossRefGoogle Scholar
  183. 184.
    Sicuteri F, Anselmi B, Curradi C, Michelacci S, Sassi A (1978) Morphine-like factors in CSF headache suffers. In: Costa E, Trabucchi M (eds) Adv Biochem Psychopharm, vol 18. Raven, New York, pp 363–366Google Scholar
  184. 184.
    Sicuteri F (1979) Headache as the most common disease of the antionociveptive system: analogies with morphine abstinence. In: Bonica JJ (ed) Advances in pain research and therapy, vol 3. Raven, New York, pp 359–365Google Scholar
  185. 185.
    Sicuteri F, Fanciullacci M, Michelacci S (1978) Decentratil-sation supersensitivity in headache and central panalge-sia. In: Friedman AP, Granger ME, Critchley M (eds) Clinical studies on headache, vol 6. Karger, Basel, pp 19–33Google Scholar
  186. 186.
    Seymour D (1993) Double-blind, placebo-controlled efficacy study of Stadol(HNS (transnasal butorphanol) and intramuscular methadone in the acute treatment of migraine. 7th World Congress of Pain. ISAP Publications, ParisGoogle Scholar
  187. 187.
    Couch J, Diamond D, Elkind A et al. (1993) Evaluation of the efficacy and safety of StadoTNS (transnasal butorphanol) in the treatment of acute migraine in outpatients. 7th World Congress on Pain. ISAP Publications, ParisGoogle Scholar
  188. 188.
    Symons IE, Emons PC, Farman JV (1982) Endogenous opioid poisoning? Br Med J 284: 469–470CrossRefGoogle Scholar
  189. 189.
    Cohen M, Pickar D, Dubois M (1982) Role of the endogenous opioid system in the human stress response. Psychiatry Clin North Am 6: 457Google Scholar
  190. 190.
    Miralles FS, Olaso MJ, Fuentes T, Lopez T, Laorden ML, Puig MM (1983) Presurgical stress and plasma endorphin levels. Anesthesiology 59: 366–367PubMedCrossRefGoogle Scholar
  191. 191.
    Laorden ML, Miralles F, Fuentes T, Lopez F, Cantera M (1984) Effects of stresstherapy on plasma beta-endorphin-like immunorectivity. Meth and Find Expl Clin Pharmacol 6: 671–674Google Scholar
  192. 192.
    Hynynen M, Lethinen A-M, Salmenperä M, Fyhrquist F, Takkunen O, Heinonmen J (1986) Continuous infusion of fentanyl or alfentanil for coronary artery surgery-Effects on plasma Cortisol concentration, ß-endorphin immuno-reactivity and arginine vasopressin. Br J Anaesth 58: 1260–1266PubMedCrossRefGoogle Scholar
  193. 193.
    Kanwal JS, Anand MB (1986) The stress response to surgical trauma: From physiological basis to therapeutic implications. Prog Food Nutr Sei 10: 67–123Google Scholar
  194. 194.
    Bloom F, Segal D, Ling N, Guillemin R (1976) Endorphins: profound behavioral effects in rats suggests new etiological factors in mental illness. Science 194: 630–632PubMedCrossRefGoogle Scholar
  195. 195.
    Günne LM, Lindström L, Terenius L (1977) Naloxone-induced reversal of schizophrenic halluzinations. J Neural Transm 40: 15CrossRefGoogle Scholar
  196. 196.
    Schenk GK, Enderes P, Engelmeier MP et al. (1978) Application of morphine antagonist naloxone in psychic disorders. Arzneimittelforsch/Drug Res 28: 1274–1277Google Scholar
  197. 197.
    Kline NS, Li CH, Lehmann E, Lajtha A, Laski E, Copper T (1977) ß-Endorphin induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34: 1111PubMedCrossRefGoogle Scholar
  198. 198.
    Van Ree JM, Otte AP (1980) Effects of ( Des-Tyr)- y-endorphin and ß-endorphin as compared to haloperidol and amphetamine on nucleus accumbens self-stimulation. Neuropharmacology 19: 429–434Google Scholar
  199. 199.
    Van Ree JM (1986) Role of pituitary and related neuropeptides in alcoholism and pharmacodependence. Prog Neu-ropsychopharmacol Biol Psychiatr 10: 219–228CrossRefGoogle Scholar
  200. 200.
    Akil H, Watson SJ, Young E (1984) Endogenous opioids. Biology and function. Ann Rev Neurosci 7: 223–255Google Scholar
  201. 201.
    Kennedy SH, Goldbloom DS (1991) Current perspectives on drug therapies for anorexia nervosa and bulemia nervosa. Drugs 41 /3: 367–377PubMedCrossRefGoogle Scholar
  202. 202.
    Spiegel TA, Stunkard AJ, Shrager WE, O’Brien CP, Morrison MF, Stellar E (1987) Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav 40 /2: 135–141PubMedCrossRefGoogle Scholar
  203. 203.
    de Zwaan M, Mitchell JE (1992) Opiate antagonists and eating behavior: a review. J Clin Pharmacol 32 /12: 1060–1072PubMedGoogle Scholar
  204. 204.
    Shaw WN, Mitch CH, Leander JD, Mendelsohn LG, Zimmerman DM (1991) The effect of the opioid antagonist LY 255–582 on body weight of the obese Zucker rat. Int J Obes Relat Metab Disord 15 /6: 387–395Google Scholar
  205. 205.
    Sandyk R (1988) Naltrexone suppresses abormal sexual behaviour in tourette’s syndrome. Int J Neurosci 43/1–2: 107–110Google Scholar
  206. 206.
    Sandman CA (1988) (3-Endorphin dysregulation in autistic and self-injurious behavior. A neurodevelopmental hypothesis. Synapse 2/3: 93–199Google Scholar
  207. 207.
    Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC (1990) Naltrexon in autistic children: a double-blind and placebo-controlled study. Psycho-pharmacol Bull 26 /1: 130–135Google Scholar
  208. 208.
    Tseng LF, Loh HH, Li CH (1976) (3-Endorphin: Cross tolerance and cross physical dependance on morphine. Proc Natl Acad Sci USA 73: 4187Google Scholar
  209. 209.
    Wei E, Loh HH (1976) Physical dependance on opiate-like peptides. Science 193: 1262PubMedCrossRefGoogle Scholar
  210. 210.
    Belluzzi JD, Stein L (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature 266: 556PubMedCrossRefGoogle Scholar
  211. 211.
    Dingledine R, Valentino RJ, Bostock E, King ME, Chang KJ (1983) Down-regulation of the 5- but not (j-opioid receptors in the hippocampal slice aassiociated with loss of physiological response. Life Sci 33: 333–336PubMedCrossRefGoogle Scholar
  212. 212.
    Tao P-L, Chang L-R, Law PY, Loh HH (1988) Decrease in 5-opioid receptor density in rat brain after chronic (D-Ala2,D-Leu5) enkephalin treatment. Brain Res 462: 313–320PubMedCrossRefGoogle Scholar
  213. 213.
    Dole VP, Nyswander M (1967) Heroin addiction - a metabolic disease. Arch Intern Med 120: 19PubMedCrossRefGoogle Scholar
  214. 214.
    Abdelhamid EE, Sultana PM, Portoghese PS, Takemori AE (1991) Selective blockade of the delta opioid receptor prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258: 299–303PubMedGoogle Scholar
  215. 215.
    Lee PHK, McNutt R, Chang K-J (1992) A nonpeptide delta-opioid receptor antagonist BW373U96, supppresses nalo-xone-precipitated morphine abstinence. Proceedings International Narcotic Research Conference (INRC), Key-stone/CO, USAGoogle Scholar
  216. 216.
    D’Amato RJ, Holaday JW (1984) Multiple opiate receptors in endotoxic shock: Evidence for 5 involvement and p-5 interactions in vivo. Proc Natl Acad Sci USA 81: 2898–2901PubMedCrossRefGoogle Scholar
  217. 217.
    Long JB, Ruvio BA, Holaday JW (1984) ICI 174,864, a novel delta antagonist, reverses endotoxic shock: Pretreatment with dynorphin (1–13) a kappa agonist, blocks this therapeutic effect. Neuropeptides 5: 292–294CrossRefGoogle Scholar
  218. 218.
    Hamilton AJ, Carr DB, La Rovere JM, Black PM (1986) Endotoxic shock elicits greater endorphin secretion than hemorrhage. Circ Shock 19: 47–54PubMedGoogle Scholar
  219. 219.
    Malcolm DS, Zaloga GP, Willey SC, Amir S, Holaday JW (1988) Naloxone potentiates epinephrine’s pressor action in endotoxemic shock. Circ Shock 25: 259–265PubMedGoogle Scholar
  220. 220.
    Holaday JW, D’Amato RJ, Ruvio BA, Feuertein G, Faden Al (1983) Adrenalectomy blocks pressure responses to naloxone in endotoxic shock. Circ Shock 11: 201–210PubMedGoogle Scholar
  221. 221.
    Malcolm DS, Zaloga GP, Willey SC, Amir S, Holaday JW (1988) Naloxone potentiates epinephrine’s pressure actions in endotoxemic rats. Circ Shock 25: 259–265PubMedGoogle Scholar
  222. 222.
    Xu T, Wang T, Han J (1992) Involvement of opioid receptors in nucleus tractus solitarii in modulating endotoxic hypotension in rats. Neurosci Lett 146 /1: 72–74PubMedCrossRefGoogle Scholar
  223. 223.
    Curtis MT, Lefer AM (1982) Beneficial action of a new opiate antagonist (Win 44,441–3) in hemorrhagic shock. Eur J Pharmacol 78: 307–313PubMedCrossRefGoogle Scholar
  224. 224.
    Feuerstein G, Faden Al, Krumins SA (1984) Alteration in opiate receptors binding after hemorrhagic shock. Eur J Pharmacol 100: 245–246PubMedCrossRefGoogle Scholar
  225. 225.
    Paciorek PM, Todd MH (1982) Comparison of the cardiovascular effects of meptazinol and naloxone following anaphylactic shock in anaesthetized rats. Br J Pharmacol 76: 245 PCrossRefGoogle Scholar
  226. 226.
    Amir S (1983) Antianaphylactic effect of naloxone in mice is mediated by increased central sympathetic outflow to sympathetic nerve endings and adrenal medulla. Brain Res 274: 180–183PubMedCrossRefGoogle Scholar
  227. 227.
    Holaday JW, Faden Al (1980) Naloxone acts at central opiate receptors to reverse hypotension, hypothermia, and hypoventilation in spinal shock. Brain Res 75: 295–300CrossRefGoogle Scholar
  228. 228.
    Faden Al, Jacobs TP, Zivin JA. Comparison of naloxone and a delta-selective antagonist in experimental spinal »stroke«. Life Sci 1983 33: 707–710PubMedCrossRefGoogle Scholar
  229. 229.
    Faden Al (1983) Opiate antagonist in the treatment of stroke. Current concepts in cerebrovascular disease. Stroke 18: 27–31Google Scholar
  230. 230.
    Groeger JS (1986) Opioid antagonists in circulatory shock. Crit Care Med 14: 170–171PubMedCrossRefGoogle Scholar
  231. 231.
    Wybran J (1985) Enkephalins and endorphins as modifiers of the immune system: present and future. Fed Proc 44: 92–94PubMedGoogle Scholar
  232. 232.
    Mathews PM, Froelich CJ, Sibbitt JWL, Brankhurst AD (1983) Enhancement of natural cytotoxicity by (3-endor-phin. J Immunol 130: 1658–1662PubMedGoogle Scholar
  233. 233.
    Gilman SC, Schwartz JM, Milner RJ, Bloom FE, Feldman JD (1982) (3-Endorphin enhances lymphozyte proliferative responses. Proc Natl Acad Sci USA 79: 4226–4230Google Scholar
  234. 234.
    Bryant HU, Bernton EW, Holaday JW (1988) Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 41: 1731–1738CrossRefGoogle Scholar
  235. 235.
    Yeager MY, Yu CT, Campbell AS, Moschella M, Guyre PM (1992) Effect of morphin and (3-endorphin on human Fc receptor-dependant and natural killer cell functions. Clin Immun Immunpath 62 /3: 336–343CrossRefGoogle Scholar
  236. 236.
    Fiatarone MA, Morley JE, Bloom EE, Benton D, Makinodan T, Salomon GF (1988) Endogenous opioids and the exercise -induced augmentation of natural killer cell activity. Lab Clin Med 112: 552–554Google Scholar
  237. 237.
    Palm S, Lehzen S, Mignat C, Steinmann J, Leimenstoll G, Maier G (1998) Does prolonged oral treatment with sustained-release morphine tablets influence immune function? Anesth Analg 86: 166–172PubMedGoogle Scholar
  238. 238.
    Carr DJJ (1991) Minireview: The role of endogenous opioids and their receptors in the immune system. Soc Expt Biol Med 37: 710–720Google Scholar
  239. 239.
    Hamel U, Kielwein G, Teschemacher H (1985) p-Casomor-phin immunoreactive material in cows milk incubated with various bacterial species. J Dairy Res 52: 139–148Google Scholar
  240. 240.
    Teschemacher H, Brantl V, Henschen A, Lottspeich F (1990) p-Casomorphin-(3-casein fragments with opioid activity: Detection and structure. In: Nyberg F, Brantl V (eds) (3-Casomorphin and related peptides. Fyris-Trych AB, Uppsala, pp 9–14Google Scholar
  241. 241.
    Volterra A, Restani P, Brunello N, Galli CL, Racagni G (1986) Interaction of ß-casomorphins with multiple opioid receptors: In vitro and in vivo studies in the newborn rat brain. Dev Brain Res 30: 25–30Google Scholar
  242. 242.
    Ramabadran K (1988) Sudden infant death syndrome and opioid peptides. Am J Dis Child 142: 12–13PubMedGoogle Scholar
  243. 243.
    Schusdziarra V, Schick A, de la Fuente A et al. (1983) Effect of ß-casomorphins and analogs on insulin release in dogs. Endocrinology 112: 885–889PubMedCrossRefGoogle Scholar
  244. 244.
    Lindström LH, Lyrenäs S, Nyberg F, Terenius L (1990) ß-Casomorphins in postpartum psychosis. In: Nyberg F, Brantl V (eds) ß-Casomorphins and related peptides. Fyris- Tryck AB, Uppsala, pp 157–162Google Scholar
  245. 245.
    Kreis GJ (1986) Physiological role of somatostatin in the digestive tract: gastric secretion, intestinal absorption, and motility. Scand J Gastroenterol 21: 47–53Google Scholar
  246. 246.
    Goldstein DB, Goldstein A. Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmac 1961 8: 48–53CrossRefGoogle Scholar
  247. 247.
    Teschemacher H (1987) Opioidrezeptoren und Opioid-peptide. Pharm Z 10: 556–567Google Scholar
  248. 248.
    Siegfried J (1988) Electrostimulation and neurosurgical measures in cancer pain. Springer, Berlin Heidelberg New York Tokio (Recent Results in Cancer Research), vol 108, pp 28–32Google Scholar
  249. 249.
    Meynadier J, Dalmas S, Lecomte JM, Gros CI, Schwartz JC (1989) Potent analgesic effect of inhibitors of enkephalin metabolism administered intrathecal to cancer patients. Pain Clin 4 /2: 201–205Google Scholar
  250. 250.
    Oye B (1985) Medikamentöse Schmerztherapie. Wiss. Buchverlag Dr. Peter Nietsch, Weiler/BingenGoogle Scholar
  251. 251.
    Teschemacher H, Schweigerer L (1985) Opioid preptides: do they have immunological significance? Trends Pharmacol Sci 6: 368–370CrossRefGoogle Scholar
  252. 252.
    Jasinski DR, Pevnik JS, Griffith JD (1978) Human pharmacology and the abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35: 501–516PubMedCrossRefGoogle Scholar
  253. 253.
    Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 197–258CrossRefGoogle Scholar
  254. 254.
    Lewis JW, Walter D (1992) Buprenorphine–background to its development as a treatment for opioid dependence. NIDA Research Monograph Series 121, pp 5–11Google Scholar
  255. 255.
    Zola EM, MacLeod DC (1983) Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm 17: 411–417PubMedGoogle Scholar
  256. 256.
    Cookson RF (1983) Carfentanil and Lofentanil. Clin Anaesthesiol 1: 156–158Google Scholar
  257. 257.
    Keup W (1983) Clonidin–seine Möglichkeiten in der Pharmakotherapie der Heroin abhängigkeit. Dtsch Ärztebl 80 /3: 25–32Google Scholar
  258. 258.
    Seevers MH (1972) Characteristics of dependence on and abuse of psychoactive drugs. In: Mule SJ, Brill H (eds) Chemical and biological aspects of drug dependence, vol 2. CRC Press, Cleveland, pp 13–21Google Scholar
  259. 259.
    Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: function and activity. Neurotransmissions 7 /1: 1–5Google Scholar
  260. 260.
    Holaday JW, Tortella FC (1984) Multiple opioid receptors: Possible physiological functions of jj and 5 binding sites in vivo. In: Genazzini AR, Müller EE (eds) Central and peripheral endorphins: Basis and clinical aspects. Raven, New York, pp 237–250Google Scholar
  261. 261.
    Martin WR (1981) Mini-Symposium II. Multiple opioid receptors. Life Sei 28: 1547–1554CrossRefGoogle Scholar
  262. 262.
    Schmidhammer H, Smith CFC, Erlach D et al. (1990) Synthesis and biological evaluation of 14-Alkoxymorphinans. 3. Extensive study on cyprodime-related compounds. J Med Chem 33: 1200–1206PubMedCrossRefGoogle Scholar
  263. 263.
    Römer D, Büscher H, Hill RC et al. (1980) Bremazocine: A potent, long-acting opiate kappa-agonist. Life Sei 27: 971–978CrossRefGoogle Scholar
  264. 264.
    Buzas B, Toth G, Cavagnero S, Hruby VJ, Borsodi A (1992) Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide [3H]deltorphin II. Life Sei 50: PL 75-PL 77Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Enno Freye
    • 1
  1. 1.Neuss-UedesheimDeutschland

Personalised recommendations